Glioblastoma
Glioblastoma multiforme, the most malignant type of brain tumour (with an incidence of 4–8 cases per 100,000 people), typically results in a fatal outcome, with an average survival time of about one year. The pathogenesis involves tumour development through various genetic pathways and the abnormal...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
IntechOpen
2026
|
| Témata: | |
| On-line přístup: | 3049-8864 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869517956159897600 |
|---|---|
| collection | Directory of Open Access Books |
| description | Glioblastoma multiforme, the most malignant type of brain tumour (with an incidence of 4–8 cases per 100,000 people), typically results in a fatal outcome, with an average survival time of about one year. The pathogenesis involves tumour development through various genetic pathways and the abnormal deregulation of growth factors, particularly IGF-I, eGFR, and PDGF. Current therapeutic strategies—including surgery, radiation, and chemotherapy—can extend survival to around 14 months, occasionally up to 18 months. More recent advancements in therapy, especially cancer gene therapy (e.g., anti-IGF-I approaches) and immunotherapy (e.g., CAR-T and checkpoint inhibitor therapies), have further increased survival times to approximately two years. Despite these promising developments, the fight against glioblastoma is ongoing and continues to require extensive research in both diagnostics and treatment. Examples of these efforts are highlighted throughout this book. The chapters emphasize the critical role of microsurgery in maintaining patient safety. In terms of innovative diagnostics, early tumour detection and precise monitoring are increasingly supported by the use of Raman spectroscopy combined with liquid biopsy. Advances in immunotherapy are also explored, including explanations of their mechanisms and the development of new vaccines, particularly those prepared using dendritic cells. Finally, considering the ongoing relevance of the COVID-19 pandemic, the book includes an important discussion on managing glioblastoma during this global health crisis. |
| format | Online |
| id | doab-20.500.12854ir-171919 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1719192026-02-12T17:27:59Z Glioblastoma Trojan, Jerzy Medical / Oncology thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Glioblastoma multiforme, the most malignant type of brain tumour (with an incidence of 4–8 cases per 100,000 people), typically results in a fatal outcome, with an average survival time of about one year. The pathogenesis involves tumour development through various genetic pathways and the abnormal deregulation of growth factors, particularly IGF-I, eGFR, and PDGF. Current therapeutic strategies—including surgery, radiation, and chemotherapy—can extend survival to around 14 months, occasionally up to 18 months. More recent advancements in therapy, especially cancer gene therapy (e.g., anti-IGF-I approaches) and immunotherapy (e.g., CAR-T and checkpoint inhibitor therapies), have further increased survival times to approximately two years. Despite these promising developments, the fight against glioblastoma is ongoing and continues to require extensive research in both diagnostics and treatment. Examples of these efforts are highlighted throughout this book. The chapters emphasize the critical role of microsurgery in maintaining patient safety. In terms of innovative diagnostics, early tumour detection and precise monitoring are increasingly supported by the use of Raman spectroscopy combined with liquid biopsy. Advances in immunotherapy are also explored, including explanations of their mechanisms and the development of new vaccines, particularly those prepared using dendritic cells. Finally, considering the ongoing relevance of the COVID-19 pandemic, the book includes an important discussion on managing glioblastoma during this global health crisis. 2026-02-12T17:27:54Z 2026-02-12T17:27:54Z 2025 book 3049-8864 9781836344308 9781836344315 9781836344322 https://directory.doabooks.org/handle/20.500.12854/171919 eng Oncology image/jpeg n/a https://www.intechopen.com/books/1004350 https://intech-files.s3.amazonaws.com/a04Tc0000084zLhIAI/0016254_Authors_Book%20%282025-10-30%2009%3A12%3A43%29.pdf IntechOpen IntechOpen 10.5772/intechopen.1005962 10.5772/intechopen.1005962 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781836344308 9781836344315 9781836344322 IntechOpen 7 160 open access |
| spellingShingle | Medical / Oncology thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Glioblastoma |
| title | Glioblastoma |
| title_full | Glioblastoma |
| title_fullStr | Glioblastoma |
| title_full_unstemmed | Glioblastoma |
| title_short | Glioblastoma |
| title_sort | glioblastoma |
| topic | Medical / Oncology thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | Medical / Oncology thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | 3049-8864 |